Advanced Or Metastatic Non-Small Cell Lung Carcinoma And Small Cell Lung Cancer
BNTXBioNTech SECatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Pumitamig/Elfetabart Drozuntecan (BNT327/BMS986545 + BNT324/DB-1311) (Bispecific ADC Combination) in Advanced Or Metastatic Non-Small Cell Lung Carcinoma And Small Cell Lung Cancer. The expected timing is based on the latest available company guidance and may change.
08/20/26:- First Ph1/2 combo data (NCT06892548) to present at WCLC Sep 15, 2026.
Verification
Confirm timing and program details against the company announcement or filing.